Filing Details

Accession Number:
0000921895-22-001555
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-05-10 17:13:49
Reporting Period:
2022-05-06
Accepted Time:
2022-05-10 17:13:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1123494 Harvard Bioscience Inc HBIO Laboratory Analytical Instruments (3826) 043306140
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1400121 W James Green C/O Harvard Bioscience, Inc.
84 October Hill Road
Holliston MA 01746
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-05-06 30,000 $3.78 2,309,955 No 4 P Direct
Common Stock Acquisiton 2022-05-09 10,000 $3.40 2,319,955 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
Footnotes
  1. This transaction was executed in multiple trades at prices ranging from $3.705 to $3.845, inclusive. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. Includes (a) 157,037 restricted stock units that will vest in three equal installments on December 29, 2022, 2023 and 2024, (b) 218,140 remaining restricted stock units that will vest on June 11, 2022 and 2023, (c) 129,799 restricted stock units that will vest in two equal installments on December 29, 2022 and 2023, (d) 109,070 remaining restricted stock units that will vest on December 29, 2022 and 2023, (e) 104,590 remaining restricted stock units that will vest on January 1, 2023, (f) 541,218 restricted stock units with performance based vesting conditions tied to relative total shareholder return and (g) 1,050,101 shares of common stock beneficially owned by the Reporting Person.
  3. This transaction was executed in multiple trades at prices ranging from $3.375 to $3.41, inclusive. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. Includes (a) the shares and awards described in footnote (2) above, and (b) the shares purchased in the transaction described in footnote (3) above.